Literature DB >> 33586614

The role and mechanism of miR-557 in inhibiting the differentiation and maturation of megakaryocytes in immune thrombocytopenia.

Yan Wang1, Yujie Guo1, Xiaolei Zhang1, Hui Zhao1, Bingbing Zhang1, Yi Wu2, Jingyu Zhang1.   

Abstract

Specific miRNA in immune thrombocytopenia (ITP) was screened to explore its intervention effects and mechanisms in ITP. MTT assay and CFSE staining were used to detect the effects of gradient concentrations of thrombopoietin (TPO) on cell proliferation. Expressions of differentially expressed miRNAs were analysed via qRT-PCR in TPO-induced megakaryocytes and ITP plasma. Effects of miR-557 on cell physiological functions were examined by MTT and flow cytometry. Expressions of miR-557, apoptosis-associated genes and Akt/ERK pathways were detected by qRT-PCR and Western blot as needed. Multinucleation of TPO-induced megakaryocytes was determined by megakaryocyte colonies. The toe skin and intestinal bleeding of the ITP rat model were observed and evaluated. Effects of miR-557 on the numbers of platelets, megakaryocytes, and peripheral blood platelets and the expressions of CD4+ T cells, Treg cells, TGF-β, IL-6 and miR-557 in the ITP rats were detected by Giemsa staining, flow cytometry, ELISA and qRT-PCR. MiR-557 was identified as an specific miRNA associated with both ITP and TPO treatment. MiR-557 inhibitor enhanced the physiological functions of TPO-induced megakaryocytes, while miR-557 mimic had the opposite effect. At the molecular level, the expressions of miR-557, cleaved Caspase-3 and Bax were further silenced by inhibitor, on the contrary, the expressions of bcl-2, p-Akt and p-ERK were upregulated. Animal experiments showed that, miR-557 inhibitor increased the numbers of platelets and megakaryocytes, and improved the symptoms of ITP model rats. Our results indicated that miR-557 inhibitor improved ITP by regulating apoptosis-related genes and cellular immunity and activating the Akt/ERK pathway.

Entities:  

Keywords:  Immune thrombocytopenia; cellular immunity; miR-557; protein kinase B/Extracellular regulated protein kinases; thrombopoietin

Mesh:

Substances:

Year:  2021        PMID: 33586614      PMCID: PMC8582991          DOI: 10.1080/15476286.2021.1884783

Source DB:  PubMed          Journal:  RNA Biol        ISSN: 1547-6286            Impact factor:   4.652


  47 in total

Review 1.  Thrombopoietin.

Authors:  K Kaushansky
Journal:  N Engl J Med       Date:  1998-09-10       Impact factor: 91.245

2.  Negative regulation of angiogenesis by novel micro RNAs.

Authors:  Veronica Sanchez; Flora Golyardi; Dominique Mayaki; Raquel Echavarria; Sharon Harel; Janguo Xia; Sabah N A Hussain
Journal:  Pharmacol Res       Date:  2018-11-08       Impact factor: 7.658

3.  Impaired Akt phosphorylation in B-cells of patients with common variable immunodeficiency.

Authors:  Reza Yazdani; Mazdak Ganjalikhani-Hakemi; Mohammad Esmaeili; Hassan Abolhassani; Shahram Vaeli; Abbas Rezaei; Zohre Sharifi; Gholamreza Azizi; Nima Rezaei; Asghar Aghamohammadi
Journal:  Clin Immunol       Date:  2016-09-21       Impact factor: 3.969

Review 4.  Severe bleeding events in adults and children with primary immune thrombocytopenia: a systematic review.

Authors:  C Neunert; N Noroozi; G Norman; G R Buchanan; J Goy; I Nazi; J G Kelton; D M Arnold
Journal:  J Thromb Haemost       Date:  2015-01-14       Impact factor: 5.824

Review 5.  Thrombopoietin receptor agonists in primary immune thrombocytopenia.

Authors:  Deborah Siegal; Mark Crowther; Adam Cuker
Journal:  Semin Hematol       Date:  2013-01       Impact factor: 3.851

Review 6.  Mitogen-activated protein kinases in innate immunity.

Authors:  J Simon C Arthur; Steven C Ley
Journal:  Nat Rev Immunol       Date:  2013-08-19       Impact factor: 53.106

Review 7.  Megakaryocytic dysfunction in immune thrombocytopenia is linked to autophagy.

Authors:  Rui-Jie Sun; Ning-Ning Shan
Journal:  Cancer Cell Int       Date:  2019-03-15       Impact factor: 5.722

8.  PARP1-Erk synergism in proliferating cells.

Authors:  Leonid Visochek; Malka Cohen-Armon
Journal:  Oncotarget       Date:  2018-06-26

9.  PD-1/PD-L1 pathway activation restores the imbalance of Th1/Th2 and treg/Th17 cells subtypes in immune thrombocytopenic purpura patients.

Authors:  Die Wu; Ying Liu; Nannan Pang; Mingling Sun; Xiujuan Wang; Yasen Haridia; Fang Zhao; Yuting Qin; Wenxia Fan; Xinhong Guo; Jianbing Ding
Journal:  Medicine (Baltimore)       Date:  2019-10       Impact factor: 1.817

View more
  1 in total

Review 1.  The Extensive Regulation of MicroRNA in Immune Thrombocytopenia.

Authors:  Yuerong Zhao; Siyuan Cui; Yan Wang; Ruirong Xu
Journal:  Clin Appl Thromb Hemost       Date:  2022 Jan-Dec       Impact factor: 3.512

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.